A trio of experts from Sinaptica Therapeutics talked about recent findings presented at CTAD 2024 from a study assessing personalized transcranial magnetic stimulation in patients with Alzheimer disease. [WATCH TIME: 5 minutes]
Emiliano Santarnecchi, PhD
Advertisement
Scientific cofounders of Sinaptica.
Articles by Emiliano Santarnecchi, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation
2
Smartphone-Based App for Muscular Relaxation Significantly Reduces Migraine-Related Disability in Emergency Room Settings
3
NeurologyLive® Friday 5 — October 24, 2025
4
Post-Stroke Recovery, GLP-1s, and Secondary Prevention
5
